KR102678264B1 - 아펠린 수용체 효능제 및 사용 방법 - Google Patents

아펠린 수용체 효능제 및 사용 방법 Download PDF

Info

Publication number
KR102678264B1
KR102678264B1 KR1020187018588A KR20187018588A KR102678264B1 KR 102678264 B1 KR102678264 B1 KR 102678264B1 KR 1020187018588 A KR1020187018588 A KR 1020187018588A KR 20187018588 A KR20187018588 A KR 20187018588A KR 102678264 B1 KR102678264 B1 KR 102678264B1
Authority
KR
South Korea
Prior art keywords
methyl
hydroxy
dihydropyrimidin
phenyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187018588A
Other languages
English (en)
Korean (ko)
Other versions
KR20180086251A (ko
Inventor
웨이 멩
한구앙 제이. 차오
헤더 핀레이
알. 마이클 로렌스
마이클 씨. 마이어스
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20180086251A publication Critical patent/KR20180086251A/ko
Application granted granted Critical
Publication of KR102678264B1 publication Critical patent/KR102678264B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020187018588A 2015-12-04 2016-12-02 아펠린 수용체 효능제 및 사용 방법 Active KR102678264B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263106P 2015-12-04 2015-12-04
US62/263,106 2015-12-04
PCT/US2016/064562 WO2017096130A1 (en) 2015-12-04 2016-12-02 Apelin receptor agonists and methods of use

Publications (2)

Publication Number Publication Date
KR20180086251A KR20180086251A (ko) 2018-07-30
KR102678264B1 true KR102678264B1 (ko) 2024-06-24

Family

ID=57570463

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187018588A Active KR102678264B1 (ko) 2015-12-04 2016-12-02 아펠린 수용체 효능제 및 사용 방법

Country Status (20)

Country Link
US (2) US11390616B2 (enExample)
EP (1) EP3383860B1 (enExample)
JP (1) JP6817305B2 (enExample)
KR (1) KR102678264B1 (enExample)
CN (1) CN108473466B (enExample)
AR (1) AR106948A1 (enExample)
AU (1) AU2016365340B2 (enExample)
BR (1) BR112018010720A8 (enExample)
CA (1) CA3007280A1 (enExample)
CL (1) CL2018001478A1 (enExample)
CO (1) CO2018006662A2 (enExample)
EA (1) EA037257B1 (enExample)
ES (1) ES2858312T3 (enExample)
HK (1) HK1255162A1 (enExample)
IL (1) IL259660B (enExample)
MX (1) MX381160B (enExample)
PE (1) PE20181269A1 (enExample)
TW (1) TW201722920A (enExample)
UY (1) UY37005A (enExample)
WO (1) WO2017096130A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
JP6356364B1 (ja) 2015-05-20 2018-07-11 アムジエン・インコーポレーテツド Ａｐｊ受容体のトリアゾールアゴニスト
PH12017502158B1 (en) 2015-06-03 2022-04-27 Bristol Meyers Squibb Co 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
WO2017066402A1 (en) 2015-10-14 2017-04-20 Bristol-Myers Squibb Company 2,4-dihydroxy-nicotinamides as apj agonists
PE20181269A1 (es) 2015-12-04 2018-08-03 Bristol Myers Squibb Co Agonistas del receptor de apelina y metodos de uso
SG11201804674UA (en) 2015-12-16 2018-06-28 Bristol Myers Squibb Co Heteroarylhydroxypyrimidinones as agonists of the apj receptor
CN109195963B (zh) 2016-03-24 2021-04-23 百时美施贵宝公司 作为apj激动剂的6-羟基-4-氧代-1，4-二氢嘧啶-5-甲酰胺
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
EP3468962A1 (en) 2016-06-13 2019-04-17 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
WO2017218617A1 (en) 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists
WO2017218633A1 (en) * 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists
JP7037558B2 (ja) 2016-10-14 2022-03-16 ブリストル－マイヤーズ スクイブ カンパニー ３－スルホニル－５－アミノピリジン－２，４－ジオール ａｐｊアゴニスト
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
EP4424364A3 (en) 2017-03-28 2024-11-27 Gilead Sciences, Inc. Methods of treating liver disease
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
CN112055713A (zh) * 2018-03-01 2020-12-08 安娜普尔纳生物股份有限公司 用于治疗与apj受体活性有关的疾病的化合物和组合物
WO2019213006A1 (en) * 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
AU2020209564B2 (en) 2019-01-15 2022-12-01 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
CN118388474A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
DE4425616A1 (de) * 1994-07-20 1996-01-25 Basf Ag Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung
JPH08325248A (ja) 1995-05-26 1996-12-10 Chugoku Kayaku Kk テトラゾール類の新規な合成試薬及びそれを用いたテトラゾール類の製造方法
CZ298812B6 (cs) 1996-07-01 2008-02-13 Dr. Reddy's Laboratories Limited Azolidindionové deriváty, způsob jejich přípravy, farmaceutické kompozice s jejich obsahem a jejich použití v léčbě diabetu a příbuzných nemocí
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
JP2004504302A (ja) 2000-07-18 2004-02-12 ニューロジェン・コーポレーション ５−置換２−アリール−４−ピリミジノン
WO2003072107A1 (en) 2002-02-22 2003-09-04 Pharmacia & Upjohn Company Substituted pyrimidinones and pyrimidinthiones
EP1620428A1 (en) 2003-04-23 2006-02-01 Pharmacia & Upjohn Company LLC Substituted pyrimidinones and pyrimidinthiones as crf antagonists
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2004305069C1 (en) 2003-12-19 2010-07-29 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US7973060B2 (en) 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
MX2008007049A (es) 2005-11-30 2008-10-23 Vertex Pharma Inhibidores de c-met y usos de los mismos.
EP1903052A3 (en) * 2006-07-28 2008-04-02 Faust Pharmaceuticals SA APJ receptor ligands and uses thereof
US9212130B2 (en) 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
US20140005181A1 (en) 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease
US20140073634A1 (en) 2012-08-24 2014-03-13 Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center Heterocyclic modulators of hif activity for treatment of disease
KR20150058284A (ko) * 2012-09-21 2015-05-28 사노피 Apj 수용체 조절자로서의 벤조이미다졸-카르복시산 아미드 유도체
PH12017502158B1 (en) 2015-06-03 2022-04-27 Bristol Meyers Squibb Co 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
WO2017066402A1 (en) 2015-10-14 2017-04-20 Bristol-Myers Squibb Company 2,4-dihydroxy-nicotinamides as apj agonists
PE20181269A1 (es) 2015-12-04 2018-08-03 Bristol Myers Squibb Co Agonistas del receptor de apelina y metodos de uso
SG11201804674UA (en) 2015-12-16 2018-06-28 Bristol Myers Squibb Co Heteroarylhydroxypyrimidinones as agonists of the apj receptor
CN109195963B (zh) 2016-03-24 2021-04-23 百时美施贵宝公司 作为apj激动剂的6-羟基-4-氧代-1，4-二氢嘧啶-5-甲酰胺
WO2017218617A1 (en) 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists
WO2017218633A1 (en) 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists
JP7037558B2 (ja) 2016-10-14 2022-03-16 ブリストル－マイヤーズ スクイブ カンパニー ３－スルホニル－５－アミノピリジン－２，４－ジオール ａｐｊアゴニスト

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chem. Ber., Vol. 109, pp. 3668-3674(1976년)*

Also Published As

Publication number Publication date
IL259660B (en) 2021-01-31
CA3007280A1 (en) 2017-06-08
TW201722920A (zh) 2017-07-01
ES2858312T3 (es) 2021-09-30
EA201891344A1 (ru) 2018-12-28
CL2018001478A1 (es) 2018-09-14
US11390616B2 (en) 2022-07-19
AR106948A1 (es) 2018-03-07
AU2016365340B2 (en) 2021-05-27
CN108473466A (zh) 2018-08-31
US20210198246A1 (en) 2021-07-01
AU2016365340A1 (en) 2018-07-19
HK1255162A1 (zh) 2019-08-09
WO2017096130A1 (en) 2017-06-08
BR112018010720A8 (pt) 2019-02-26
PE20181269A1 (es) 2018-08-03
CN108473466B (zh) 2022-04-19
IL259660A (en) 2018-07-31
BR112018010720A2 (pt) 2018-11-21
MX2018006217A (es) 2018-08-01
MX381160B (es) 2025-03-12
US20220315569A1 (en) 2022-10-06
UY37005A (es) 2017-06-30
JP2018535999A (ja) 2018-12-06
EP3383860B1 (en) 2021-01-20
CO2018006662A2 (es) 2018-07-10
EA037257B1 (ru) 2021-02-26
JP6817305B2 (ja) 2021-01-20
KR20180086251A (ko) 2018-07-30
US12168655B2 (en) 2024-12-17
EP3383860A1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
KR102678264B1 (ko) 아펠린 수용체 효능제 및 사용 방법
KR102433280B1 (ko) Apj 효능제로서의 6-히드록시-4-옥소-1,4-디히드로피리미딘-5-카르복스아미드
KR102742744B1 (ko) Apj 수용체의 효능제로서의 헤테로아릴히드록시피리미디논
KR102384668B1 (ko) Apj 효능제로서의 6-히드록시-5-(페닐/헤테로아릴술포닐)피리미딘-4(1h)-온
KR102521956B1 (ko) 3-술포닐-5-아미노피리딘-2,4-디올 apj 효능제
KR102066336B1 (ko) 심혈관 장애의 치료에 사용하기 위한 4-히드록시-3-(헤테로아릴)피리딘-2-온 apj 효능제
KR102521955B1 (ko) Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온
KR102707502B1 (ko) Apj 효능제로서의 2,4-디히드록시-니코틴아미드

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180629

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211130

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231124

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240321

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240620

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240620

End annual number: 3

Start annual number: 1

PG1601 Publication of registration